1. Search Result
Search Result
Results for "

Calu-6

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137246

    CD73 Cancer
    CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research .
    CD73-IN-3
  • HY-W010320

    2-Ethyl-3-hydroxy-4H-pyran-4-one

    Environmental Pollutants Apoptosis Heme Oxygenase (HO) Others
    Ethyl maltol (2-Ethyl-3-hydroxy-4H-pyran-4-one) is an orally active and important food additive and flavor enhancer. Ethyl maltol is less toxic to rats and dogs. Ethyl maltol can enhance copper-mediated cytotoxicity and induce apoptosis in lung epithelial cells .
    Ethyl maltol
  • HY-148819A

    ADC Payload Topoisomerase Cancer
    NH2-bicyclopentane-7-MAD-MDCPT hydrochloride (Formula I) is a topoisomerase I (TOP1) inhibitor. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is applicable to the synthesis of the ADC ABBV-969. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is used in research on lung adenocarcinoma and melanoma .
    NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride
  • HY-144269

    Raf Cancer
    SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC50s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF wt, and bRAF V600E, respectively. SHR902275 shows cell growth inhibition with GI50s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively .
    SHR902275
  • HY-W509563

    Ferroptosis Neurological Disease
    Frataxin-in-1 (Compound (+)-11) is a Frataxin inhibitor with IC50 value of 45 μM, which can be used in the study of Friedreich's ataxia (FRDA) .
    Frataxin-IN-1
  • HY-160649

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-Gly-Gly-Phe-Gly-GABA-Exatecan is an agent linker conjugate for ADC, with an inhibitor for Topoisomerase Exatecan (HY-13631) with IC50 of 22 μM. MC-Gly-Gly-Phe-Gly-GABA-Exatecan targets various antibodies, exhibits cytotoxic and antitumor efficacy in vitro and in vivo .
    MC-Gly-Gly-Phe-Gly-GABA-Exatecan
  • HY-170850

    Kinesin Cancer
    MKLP2-IN-1 (compound 12a) is an inhibitor of MKLP2 with good oral bioavailability. MKLP2-IN-1 inhibits the microtubule-stimulated ATPase activity of recombinant MKLP2 in vitro and suppresses tumor growth in a mouse Calu-6 lung cancer model .
    MKLP2-IN-1
  • HY-18165

    LPL Receptor Cancer
    XL541 is a potent, selective S1P1 antagonist. XL541 inhibits GDP-GTP exchange. XL541 causes frank surface hemorrhaging of tumors. XL541 collaborates with Paclitaxel (HY-B0015) to exhibit antitumor activity against breast cancer and lung cancer .
    XL541
  • HY-119992

    PARP Cancer
    CEP-6800 is an inhibitor of PARP-1 with chemopotentiating ability. CEP-6800 attenuates irinotecan (HY-16562)- and Temozolomide (HY-17364)-induced poly(ADP-ribose) accumulation in LoVo as well as HT29 xenografts. CEP-6800 can suppress Calu-6 tumor growth. CEP-6800 can be studied in anti-cancer research .
    CEP-6800
  • HY-145402

    CDK Cancer
    CDK7-IN-7 is a potent and selective CDK7 kinase inhibitor with an IC50 of <50 nM (Patent CN112661745A, compound T-01) .
    CDK7-IN-7
  • HY-170349

    Ligands for Target Protein for PROTAC SWI/SNF Complex Cancer
    SMARCA2 ligand-11 is the ligand for SMARCA2, and can be used for synthesis of PROTAC SMARCA2 degrader-32 (HY-170343) as ligand for target protein .
    SMARCA2 ligand-11
  • HY-170343

    PROTACs SWI/SNF Complex Cancer
    PROTAC SMARCA2 degrader-32 (Compound 27) is the degrader for SMARCA2 with a DC50 of 1.3 nM. PROTAC SMARCA2 degrader-32 inhibits the proliferation of lung cancer cell NCI-H838 with a GI50 of 34 nM . (Pink: ligand for target protein SMARCA2 ligand-11 (HY-170349); Black: linker (HY-W895794); Blue: ligand for E3 ligase VHL (HY-170348))
    PROTAC SMARCA2 degrader-32
  • HY-170347

    PROTACs Epigenetic Reader Domain Cancer
    PROTAC SMARCA2/4 degrader-36 (Compound 29) is an effective dual degrader of SMARCA2/4,with DC50 values of 0.22 nM and 0.85 nM for SMARCA2 and SMARCA4, respectively. PROTAC SMARCA2/4 degrader-36 has anti-cell proliferation activity (Pink: Target Protein Ligand (HY-170354); Black: Linker (HY-W895794); Blue: E3 Ligase Ligand (HY-170353); E3 Ligase Ligand-Linker Conjugate (HY-170356)) .
    PROTAC SMARCA2/4 degrader-36
  • HY-N3950

    Microtubule/Tubulin Cancer
    Glochidiol is an orally active tubulin polymerization inhibitor with an IC50 of 2.76 μM. Glochidiol shows anti-cancer activity .
    Glochidiol
  • HY-170352

    E3 Ligase Ligand-Linker Conjugates Cancer
    E3 Ligase Ligand-linker Conjugate 150 is the conjugate of the ligand for E3 ligase VHL and the linker, that can be used for synthesis of PROTAC SMARCA2 degrader-32 (HY-170343) .
    E3 Ligase Ligand-linker Conjugate 150
  • HY-183186

    METTL3 Cytochrome P450 Cancer
    EP102 is an orally active, selective inhibitor of the METTL3/METTL14 complex with an IC50 of 2 nM. EP102 reduces intracellular N6-methyladenosine levels, inhibits cancer cell proliferation, and thereby suppresses tumor growth in mouse models. EP102 is applicable for the research of acute myeloid leukemia, ovarian solid tumors and advanced solid tumors .
    EP102
  • HY-181567

    METTL3 Cancer
    METTL3-IN-13 is a METTL3 inhibitor. METTL3-IN-13 is applicable to the research of multiple cancers such as hypopharyngeal squamous cell carcinoma and non-small cell lung cancer .
    METTL3-IN-13

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: